ProCE Banner Activity

Safety Monitoring of Treatment for NTM Lung Disease

Clinical Thought
Attention to safety concerns for patients receiving treatment for NTM lung disease is paramount. Here are some of the steps I take while following patients as they undergo treatment.

Released: November 30, 2021

Expiration: November 29, 2022

No longer available for credit.

Share

Faculty

Princy N. Kumar

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Insmed Incorporated

Partners

NTMIR

ProCE Banner

Faculty Disclosure

Primary Author

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

Princy N. Kumar, MD, FIDSA, MACP, has disclosed that she has received funds for research support from Amgen, Gilead Sciences, GlaxoSmithKline, and Merck; consulting fees from Amgen, GlaxoSmithKline, and Merck; and has ownership interests in Gilead Sciences, Johnson & Johnson, Merck, and Pfizer.